The first case of third-generation cephalosporins resistant Kluyvera ascorbata biliary tract infection in Japan: A case report and review of the literature
Author(s) -
Yoshikazu Mutoh,
Tomohisa Kobe,
Tomoya Hirano,
Toshihiko Ichihara,
Hiroyuki Takenaka,
Takuro Niinomi,
Takumi Umemura,
Masanori Kuroiwa
Publication year - 2019
Publication title -
idcases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.319
H-Index - 13
ISSN - 2214-2509
DOI - 10.1016/j.idcr.2019.e00498
Subject(s) - cephalosporin , medicine , ceftriaxone , antibiotics , microbiology and biotechnology , levofloxacin , bacteremia , sepsis , ciprofloxacin , pathogen , biology , immunology
Kluyvera ascorbata is a gram-negative, catalase-positive, oxidase-negative, aerobic fermentative bacterium with flagella. This organism colonizes in the human body and its pathogenicity is extremely low; few clinical cases of K. ascorbata infection have been reported. Presentation of case We report on a patient who experienced severe sepsis and acute cholangitis due to K. ascorbata bacteremia and was treated with levofloxacin following antibiotic susceptibility testing. To our knowledge, this is the first case report of third-generation cephalosporins resistant K. ascorbata infection in Japan. Discussion Although this pathogen produces innate CTX-M type β-lactamases and is generally resistant to first- and second-generation penicillins and cephalosporins, multi-drug resistant K. ascorbata infection, including ceftriaxone resistant infection has seldom been reported. Conclusion The increase of drug-resistant pathogens is of concern; in such cases, rapid microbial identification and appropriate antibiotic selection are crucial for successful treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom